autoimmune-diseases
(3)
Allison Luo
Allison Luo, MD is the Chief Medical Officer of Mirador Therapeutics, a San Diego precision-medicine company that launched in 2024 with more than $400 million to attack immuno-fibrotic diseases using its Mirador360 development engine. A physician scientist with more than two decades in clinical development, she was CMO of Prometheus Biosciences before Merck bought it for $10.8 billion, and has since reassembled with that team to build Mirador. She sits on the board of Triveni Bio and has held medical-leadership roles across Ventyx, Biora, Iveric Bio and Bristol Myers Squibb.
BlossomHill Therapeutics, Inc.
BlossomHill Therapeutics is a San Diego clinical-stage biopharmaceutical company designing small-molecule precision medicines for cancer and autoimmune disease. Founded in 2020 by drug designer J. Jean Cui and biotech veteran Y. Peter Li - the team behind Turning Point Therapeutics (acquired by Bristol Myers Squibb in 2022) - the company is advancing a wholly-owned pipeline led by BH-30643, a first-in-class macrocyclic OMNI-EGFR inhibitor for EGFR-mutant non-small cell lung cancer, and BH-30236, a CLK inhibitor targeting aberrant RNA splicing in AML and high-risk MDS.
GlycoEra AG
GlycoEra AG is a Swiss-American clinical-stage biotech building a new class of precision medicines that selectively degrade the circulating proteins driving autoimmune disease. Spun out of LimmaTech Biologics in 2021 and powered by a proprietary glycoengineering platform, the company designs bifunctional biologics (G-LyTACs) that pull pathogenic autoantibodies out of the bloodstream with speed and depth - without the broad immune suppression of existing therapies. Its lead program, GE8820, targets pathogenic IgG4 autoantibodies. Backed by $179M across Series A and an oversubscribed $130M Series B, GlycoEra operates from Wädenswil, Switzerland and Newton, Massachusetts.